Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H13F2NO3 |
| Molecular Weight | 293.2654 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(F)C=C(OC2=CC=C(C=C2F)C(N)=O)C(O)=C1
InChI
InChIKey=QUHARGDBJJUOEB-UHFFFAOYSA-N
InChI=1S/C15H13F2NO3/c1-2-8-6-12(19)14(7-10(8)16)21-13-4-3-9(15(18)20)5-11(13)17/h3-7,19H,2H2,1H3,(H2,18,20)
| Molecular Formula | C15H13F2NO3 |
| Molecular Weight | 293.2654 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:48:12 UTC 2023
by
admin
on
Sat Dec 16 09:48:12 UTC 2023
|
| Record UNII |
B52RPV7VRM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1269055-85-7
Created by
admin on Sat Dec 16 09:48:12 UTC 2023 , Edited by admin on Sat Dec 16 09:48:12 UTC 2023
|
PRIMARY | |||
|
300000041507
Created by
admin on Sat Dec 16 09:48:12 UTC 2023 , Edited by admin on Sat Dec 16 09:48:12 UTC 2023
|
PRIMARY | |||
|
FAB-001
Created by
admin on Sat Dec 16 09:48:12 UTC 2023 , Edited by admin on Sat Dec 16 09:48:12 UTC 2023
|
PRIMARY | Biological Activity of MUT056399:MUT056399 is a highly potent inhibitor of the FabI enzyme of both S. aureus and E. coli with 50% inhibitory concentration IC50s of 12 nM and 58 nM, respectively.;IC50 value: 12 nM (for S. aureus), 58 nM (for E. coli);Target: FabI enzyme;in vitro: MUT056399 is a highly potent new inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli. MUT056399 is very active against S. aureus strains, including methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), linezolid-resistant, and multidrug-resistant strains, with MIC90s between 0.03 and 0.12 .MU.g/ml. MUT056399 is also active against coagulase-negative staphylococci, with MIC90s between 0.12 and 4 .MU.g/ml. MUT056399 is very active against the 118 S. aureus strains tested, including MSSA and MRSA isolates and linezolid-resistant and multidrug-resistant strains, with MIC90s between 0.03 and 0.12 .MU.g/ml. | ||
|
B52RPV7VRM
Created by
admin on Sat Dec 16 09:48:12 UTC 2023 , Edited by admin on Sat Dec 16 09:48:12 UTC 2023
|
PRIMARY | |||
|
44208849
Created by
admin on Sat Dec 16 09:48:12 UTC 2023 , Edited by admin on Sat Dec 16 09:48:12 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Mutabilis; Developer: FAB Pharma; Class: Antibacterial, Benzamide, Phenol, Phenyl ether, Small molecule; Mechanism of Action: Enoyl-ACP reductase inhibitor; Highest Development Phase: Phase I for Methicillin-resistant Staphylococcus aureus infections; Most Recent Events: 12 Sep 2012 Antimicrobial data from a Preclinical trial in Acinetobacter infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012), 17 Sep 2011 Pharmacokinetics data from a preclinical trial presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011), 07 May 2011 Pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy (ECCMID/ICC-2011)
|
